An interventional study of Collaborative Virtual Environment and Non-Immersive Virtual Reality (NIVR) in Parkinson Desease, sponsored by Superior University. Recruiting at 1 site in Pakistan. Open to participants aged 45 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-04-15.
Sponsored by Superior University · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Parkinson Disease with a site in Pakistan — 14 open to participants now, 15 under way, none of them phase 3. Parkinson Disease · Pakistan.
Among the 34 studies in Parkinson Disease with a site in Pakistan, this one is the 7th largest by planned enrollment of the 30 interventional ones that give a count, is one of 2 that started in 2025, is one of 30 with no phase, reaches primary completion later than 11 of the 14 other live ones, and was the 30th registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →14 of the 34 studies in Parkinson Disease with a site in Pakistan are open now. Recruiting first, the newest first:
safia bano · Sites in Pakistan
Ages 40–70
Lahore University of Biological and Applied Sciences · Sites in Pakistan
Ages 50–65
University of Health Sciences Lahore · Sites in Pakistan
Ages 45–85
Rumesa Butt · Sites in Pakistan
Ages 45–55
University of Lahore · Sites in Pakistan
Ages 50–70
A study can be open while its sites in Pakistan have not opened yet or have stopped. Only those recruiting at a site in Pakistan →
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 45 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
First in 2019; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is above the median of 40 across 3,360 interventional studies indexed under Parkinson Disease.
Median enrollment 42 across the 30 interventional studies, 138 across the 4 observational. Of the 17 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 34 has an industry lead sponsor. The 10 most frequent:
Superior University is the lead sponsor of 253 studies on the registry; 25 are open to participants now.
Superior University has 3 studies filed under Parkinson Disease — fewer than ten, so there is no comparison to draw.
1 of the studies in Parkinson Disease with a site in Pakistan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07810296safia banoComparison of Benzhexol and Procyclidine for Tremor in Tremor-Predominant Parkinson's Disease | 2027-07 |
Add it to your calendar (.ics) → With an account.
Among the 34 studies in Parkinson Disease with a site in Pakistan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This randomized controlled trial aims to compare the effectiveness of a Collaborative Virtual Reality Environment (CVE) and Non-Immersive Virtual Reality (NIVR) in the rehabilitation of patients with Parkinson's disease. Participants with mild to moderate disease severity will be randomly assigned to either the CVE group or the NIVR group.
The CVE intervention will involve therapist-guided, interactive virtual exercises in a shared environment, promoting real-time engagement and feedback. The NIVR group will perform task-oriented exercises using screen-based virtual reality without immersive and collaborative features.
Both interventions will be delivered over an 12-week period. Primary outcomes will assess motor function using standardized clinical scales, while secondary outcomes will evaluate cognitive function, mobility, and quality of life.
The study seeks to determine whether collaborative and interactive virtual rehabilitation provides superior clinical outcomes compared to conventional non-immersive virtual approaches in patients with Parkinson's disease.
This study is designed to investigate the comparative therapeutic value of two distinct virtual reality-based rehabilitation teatement in individuals diagnosed with Parkinson's disease. The focus is on understanding how differences in interaction design, immersion level, and therapist involvement influence clinical outcomes.
The intervention framework is structured around task-oriented, goal-directed activities targeting both motor and cognitive domains commonly affected in Parkinson's disease. The Collaborative Virtual Reality Environment (CVE) incorporates a shared virtual space where the patient and therapist interact synchronously. This setup enables real-time guidance, adaptive feedback, and enhanced engagement through social and therapeutic presence. In contrast, the Non-Immersive Virtual Reality (NIVR) condition delivers similar rehabilitation tasks via a conventional screen-based interface without immersive or collaborative elements, relying primarily on self-directed patient interaction.
The rehabilitation protocol emphasizes functional movement patterns, including upper limb coordination, gait-related tasks, and balance. The virtual exercises are designed to align with established neurorehabilitation principles such as repetition, task specificity, and feedback-driven motor learning. Progression within the intervention is structured through graded task difficulty and performance-based adjustments.
Outcome evaluation focuses on quantifying changes in motor performance, cognitive function, functional mobility, and health-related quality of life using validated clinical instruments. Data will also be used to explore the relationship between user engagement characteristics and rehabilitation outcomes.
The study aims to generate evidence on whether integrating collaboration and immersion into virtual rehabilitation environments offers clinically meaningful advantages over conventional non-immersive approaches, thereby informing future design and implementation of technology-assisted neurorehabilitation systems.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this arm will receive rehabilitation through a Collaborative Virtual Reality Environment (CVE), where both the patient and therapist interact simultaneously within a shared virtual space. The intervention is delivered using a head-mounted display-based system that enables real-time communication, guidance, and feedback. The rehabilitation program consists of task-specific, goal-oriented exercises targeting upper limb function, gait, balance, and functional mobility. Activities are designed to simulate real-world movements and include object manipulation, reaching tasks, and controlled walking scenarios. The therapist actively supervises and adapts the exercises during each session, ensuring appropriate progression based on patient performance. The collaborative nature of the environment facilitates increased engagement, motor learning, and adherence by incorporating interactive elements and immediate corrective feedback. The intervention follows structured progressio
Other: Collaborative Virtual Environment
Participants in this arm will undergo rehabilitation using a Non-Immersive Virtual Reality (NIVR) system delivered through a standard screen-based interface. The intervention without the use of head-mounted displays or real-time collaborative features. The rehabilitation program includes task-oriented exercises focusing on upper limb function, balance, gait-related activities, and overall functional mobility. These exercises are designed to replicate real-world movements and are performed in a structured and repetitive manner to promote motor learning. Participants will perform the activities independently with periodic supervision from a therapist. Feedback is primarily system-generated, and progression is based on predefined levels of difficulty within the software. The intervention emphasizes consistency, task specificity, and gradual progression throughout the study
Other: Non-Immersive Virtual Reality (NIVR)
Collaborative Virtual Reality Environment (CVE), participants perform exercises within a shared virtual space alongside a therapist, enabling real-time interaction, guidance, and adaptive feedback.
Physiotherapy-based rehabilitation delivered through a screen-based virtual environment, involving structured, task-oriented exercises performed with limited therapist interaction
MDS-UPDRS-III
The MDS-UPDRS-III is a clinician-administered scale used to assess motor impairment in individuals with Parkinson's disease. It evaluates key domains including bradykinesia, rigidity, tremor, postural stability, and gait through a series of standardized physical examination items. Each item is scored on a 5-point ordinal scale ranging from 0 (normal) to 4 (severe impairment), with higher total scores indicating greater motor dysfunction. The scale provides a comprehensive measure of motor severity and is widely used in both clinical and research settings due to its strong reliability and validity. Changes in MDS-UPDRS-III scores over time will be used to determine the effectiveness of the intervention in improving motor function.
Time frame: From enrollment to the end of treatment at12 weeks
Timed Up and Go (TUG) Test
The Timed Up and Go (TUG) Test is a standardized clinical measure used to assess functional mobility, balance, and risk of falls in individuals with Parkinson's disease. The test requires the participant to stand up from a seated position, walk a distance of approximately 3 meters, turn around, walk back to the chair, and sit down. The total time taken to complete the task is recorded in seconds. Shorter completion times indicate better functional mobility and balance performance, whereas longer times may reflect impaired mobility and increased fall risk. The TUG test is widely recognized for its simplicity, reliability, and sensitivity to changes following rehabilitation interventions.
Time frame: Assessed at baseline (pre-intervention) and at the end of the intervention period (12 weeks)
Falls Efficacy Scale-International (FES-I)
The Falls Efficacy Scale-International (FES-I) is a standardized, self-reported questionnaire used to assess concern about falling during a range of daily activities in individuals with movement disorders, including Parkinson's disease. It evaluates both basic and more demanding physical and social activities, providing a comprehensive measure of fall-related self-efficacy. The scale consists of 16 items, each scored on a 4-point Likert scale ranging from 1 (not at all concerned) to 4 (very concerned). The total score ranges from 16 to 64, with higher scores indicating greater fear of falling and lower confidence in performing daily activities safely. The FES-I has demonstrated strong reliability, validity, and cross-cultural applicability in clinical and research settings.
Time frame: Assessed at baseline (pre-intervention) and at the end of the intervention period (12 weeks)
Parkinson's Disease Fatigue Scale (PFS-16)
The Parkinson's Disease Fatigue Scale (PFS-16) is a disease-specific, self-reported instrument used to evaluate the impact and severity of fatigue in individuals with Parkinson's disease. It consists of 16 items focusing on physical fatigue and its effect on daily functioning. Scores are calculated based on patient responses, with higher scores indicating greater fatigue severity. Scale generally uses a 1-5 scoring system, resulting in minimum and maximum average scores of 1.0 (no fatigue) and 5.0 (extreme fatigue), respectively, with minimum 16 and maximum 80 Score.
Time frame: Assessed at baseline (pre-intervention) and at the end of the intervention period (12 weeks)
Action Research Arm Test (ARAT)
The Action Research Arm Test (ARAT) is a performance-based assessment used to evaluate upper limb function. It measures the ability to perform tasks involving grasp, grip, pinch, and gross arm movement through a series of standardized activities. Each task is scored on an ordinal scale, with higher scores indicating better upper limb function and coordination. The tool assess upper extremity performance, with a total score range from 0 to 57.
Time frame: Assessed at baseline (pre-intervention) and at the end of the intervention period (12 weeks)
Started May 2025 (actual). Primary completion is estimated for Sep 2026, 16 months after the start.
Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 16 months is below that.
Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.